Please ensure Javascript is enabled for purposes of website accessibility

Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015

By Brian Feroldi - Jan 13, 2016 at 7:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clinical progress doesn't always translate into a higher share price.

What: Shareholders of Idera Pharmaceuticals (IDRA 5.13%), a clinical-stage biopharmaceutical company focused on cancer and other rare diseases, had a rough 2015. The company's shares lost more than 36% of their value in during the year, according to data from S&P Capital IQ.

IDRA Chart

So what: The company's poor share price performance is surprising considering all of the positive news items it released during the year. Here are a few highlights long-term investors should be aware of:

  • The FDA granted orphan drug designation for IMO-8400, Idera's compound that is being researched as a treatment for diffuse large B-cell lymphoma. Landing an orphan drug designation usually allows a company to earn tax credits or gain longer periods of marketing exclusivity if the drug finds its way to market.  
  • IMO-8400 is also being studied as a potential treatment for Dermatomyositis, a rare inflammatory muscle and skin disease. During the year, the company initiated a phase 2 clinical trial to study its usefulness in treating the disease. 
  • The company reported promising data from its ongoing Phase 1/2 clinical trial for IMO-8400 as a treatment for patients with relapsed or refractory Waldenström's Macroglobulinemia.  
  • Idera successfully completed a Phase 1 trial that demonstrated that IMO-9200, a compound that may be used to treat inflammatory bowel disease, was safe and well tolerated across all tested dosages.
  • The company entered into a strategic clinical alliance with MD Anderson Cancer Center to advance research on IMO-2125, Idera's TLR9 agonist, which is being studied in the exciting field of immuno-oncology.
  • Idera signed an agreement with pharma giant GlaxoSmithKline (GSK -4.32%) to identify third-generation antisense molecules to be used to treat renal disease. GlaxoSmithKline provided Idera with an initial payment of $2.5 million and set up potential milestones that could send another $100 million Idera's way. If the product's annual net sales exceed $500 million, GlaxoSmithKline will be on the hook to pay up to 5% in royalties. 

Add it all up, and Idera had a productive year.

Now what: While the clinical updates and its new partnerships with MD Anderson Cancer Center and GlaxoSmithKline are encouraging, I think investors should approach this stock with caution. The value of this company is still heavily tied up in its early-stage pipeline, so even if all goes well, it will still be years before the company will be able to produce meaningful revenue. The company is also on pace to burn through nearly $50 million in cash in 2015, and with only $95 million on its books as of September, it's likely that it will have to raise capital in the next year or two.

History isn't on investors' side here, either, as Idera has been a publicly traded company for nearly 20 years now, and long-term investors do not have much to show for their patience.

IDRA Chart

For all those reasons, I would like to see the company move its compounds a bit further along the clinical pathway before I'd even consider putting this company on my radar.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Idera Pharmaceuticals, Inc. Stock Quote
Idera Pharmaceuticals, Inc.
IDRA
$0.47 (5.13%) $0.02
GSK Stock Quote
GSK
GSK
$38.30 (-4.32%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.